Merck & Co. said a key European regulatory committee has recommended conditional approval of its Welireg oral cancer drug in a pair of indications.

Ionis Pharmaceuticals is advancing the investigational RNA-targeted therapy olezarsen for the treatment of familial ...

Sorafenib is US FDA approved for the treatment of advanced renal cell carcinoma and unresectable hepatocellular carcinoma. The recommended single-agent dose is 400 mg orally twice a day ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Kidney Cancer Session II. Dr Mark Ball discussed ...

Amid its plummeting stock value, layoffs and cuts to its drug R&D program, the battered company is carrying on.

Consistent with the principles of the 3Rs in Animal Experimentation (Hubrecht and Carter, Animals (Basel) 2019, 9, 754) ...

LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial ...

The tyrosine kinase inhibitors market is expected to grow significantly over the next decade, driven by continued innovation, rising cancer awareness, and increased adoption of targeted therapies.

Mapping of splicing quantitative trait loci revealed context-specific regulation of alternative splicing, as well as cell-type and ancestry-specific genetic effects on complex diseases.

LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial ...

People who are younger and/or diagnosed before the cancer spreads outside the lung generally have a better prognosis. There are two main types of lung cancer: non-small cell lung cancer and small cell ...